Miura, Kazutoyo
Diouf, Ababacar
Fay, Michael P.
Barrett, Jordan R.
Payne, Ruth O.
Olotu, Ally I.
Minassian, Angela M.
Silk, Sarah E.
Draper, Simon J.
Long, Carole A.
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases
United States Agency for International Development
NIHR Oxford Biomedical Research Centre
National Institutes of Health
Article History
Received: 14 February 2023
Accepted: 16 May 2023
First Online: 19 May 2023
Declarations
:
: The VAC057 study was reviewed and approved by the Oxfordshire Research Ethics Committee A in the UK (REC reference 14/SC/0120) and by the UK Medicines and Healthcare products Regulatory Agency (MHRA, reference 21584/0331/001-0001). The VAC063 study was reviewed and approved by the UK NHS Research Ethics Service (Oxfordshire Research Ethics Committee A, Ref 16/SC/0345) and by the UK Medicines and Healthcare products Regulatory Agency (Ref 21584/ 0362/001–0011). The VAC070 study was approved by the Oxford Tropical Research Ethics Committee (OxTREC, reference 29–17), the Ifakara Health Institute Institutional Review Board (IHI-IRB, reference 20–2017), the Tanzanian National Health Research Ethics Sub-Committee / National Institute for Medical Research (NatHREC/NIMR, reference NIMR/HQ/R8a/Vol. IX/2643), and the Tanzania Food and Drug Authority (TFDA, now known as the Tanzania Medicines and Medical Devices Authority, TMDA, reference TFDA0017/CTR/0015/3).In all three trials, written informed consent was obtained from study participants or the parents or guardians of children aged < 18 years (in the VAC070 study each participant signed or thumb-printed an informed consent form at the in-person screening visit).
: Not applicable.
: S.J.D. is named inventors on patent applications relating to RH5 and/or other malaria vaccines and immunization regimens. A.M.M. has an immediate family member who is an inventor on patents relating to RH5 and/or other malaria vaccines and immunization regimens.